The company has secured additional active pharmaceutical ingredient for its digoxin tablets, 0.125mg and 0.25mg. Digoxin is indicated for the treatment of mild to moderate heart failure as well as for the control of ventricular response rate in patients with chronic atrial fibrillation.
Arthur Bedrosian, president and CEO of Lannett, said: “We want to reassure all of our customers as well as the general public that we are prepared to supply this difficult to source medication.”